Skip to main content
. 2022 Sep 13;149(8):4347–4358. doi: 10.1007/s00432-022-04330-5

Table 2.

Validation of rare cell abnormality criterion

Healthy Non-malignant Pre-treatment cancer Mid-treatment cancer Treatment completion cancer
Abnormality by cell quantity 0/9 3/4 6/9 3/3 3/3
Abnormality by Cd44i35 0/9 2/4 7/9 3/3 3/3
CD44i35/CD44+ CRC ratio Not relevant 5.2% 41.8% 46.1% 37.1%
Average morphological index 15.7 12.8 40.0 114 221